Lentiviral Expression
LentiBOOST® is a highly effective, non-cytotoxic transduction enhancer for preclinical and clinical application of lentiviral vectors. As universally acting (receptor independent) adjuvant it can be applied to a wide range of clinically relevant cell types including CD34+ hematopoietic stem cells (HSCs), primary T cells and NK cells. These unique features make it a promising candidate to improve clinical transduction protocols for ex vivo gene therapies and CAR-T cell therapies.
The substance has become the gold standard for lentiviral transduction of HSCs. Latest results show consistently increased VCN (Vector Copy Number) per cell in the range of 3 copies per genome and high gene expression in patients 6 month after HSC therapy. This effect of an increase of vector copy numbers can also be observed for T-cells, leading to a higher transduction efficiency applying LentiBOOST®, which in return allows higher levels of expression of your therapeutic proteins.
LentiBOOST® research grade material is used for basic research only - not transferable to the clinic
LentiBOOST® pharma grade non-GMP material is used for preclinical research and process development including large scale runs
LentiBOOST® GMP material is for clinical use - Sirion holds a patent (published as WO2013127964) for this substance class and licenses the technology for clinical use. LentiBOOST® GMP material is available for process development (GMP pilot runs) under a research or clinical license. Please contact lentiboost@sirion-biotech.de
LentiBOOST-R__Manual_English_V4.1_MFB.pdf
LentiBOOST-P_Manual_English_V5.6_MFB.pdf
Featured products within Lentiviral Expression

- New: Coronavirus Research Tools
- Ebola Antibodies and Antigens
- LentiBOOST pharma grade non-GMP material
- Multiplexed bead-based immunoassays
- C-Slide - The New Name for Countess Slides
- New: PODS™ - Slow Release Growth Factors
- New: C80EZ Cryopreservation Media - -80C Safe Cell Storage
- RNA Extraction Kit from Fresh Cells
